BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
about
Polo-like kinase-1 controls Aurora A destruction by activating APC/C-Cdh1Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulationPolo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formationPlk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cellsPolo-like kinase is required for synaptonemal complex disassembly and phosphorylation in mouse spermatocytesThe novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolusPharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia proteinPhosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADDPolo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4 triggers centriole duplicationPolo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5ANuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent mannerPlk1-dependent recruitment of gamma-tubulin complexes to mitotic centrosomes involves multiple PCM componentsA genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogeneA panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Targeting protein serine/threonine phosphatases for drug developmentPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisPutting a bit into the polo-box domain of polo-like kinase 1Volasertib for AML: clinical use and patient considerationPolo-like kinase 1, on the rise from cell cycle regulation to prostate cancer developmentDiscovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyMolecular dynamics of PLK1 during mitosisA high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitroPlk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell linesPP2A-twins is antagonized by greatwall and collaborates with polo for cell cycle progression and centrosome attachment to nuclei in drosophila embryosSmall-molecule kinase inhibitors provide insight into Mps1 cell cycle functionAcetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase InhibitorsDual kinase-bromodomain inhibitors for rationally designed polypharmacologySelective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brainPLK1, A Potential Target for Cancer TherapyPolo-like kinase 1 licenses CENP-A deposition at centromeresCurrent prospects for RNA interference-based therapiesA mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpointA series of beta-carboline derivatives inhibit the kinase activity of PLKsA simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assaysTargeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory AnalysisStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayDrug Discovery Targeting Bromodomain-Containing Protein 4.
P2860
Q21090068-3A3E67D9-262E-44D2-ADCA-BB1A02AFD2DCQ21092524-28E84899-BB25-4645-9DAA-4930AB1E20AFQ21092734-0065B5C6-1C3F-4FD2-97CA-7AE583F1B03EQ21563540-BA5F17F3-CA3A-47BD-9E2F-9070C3333370Q24294615-DDB6D5D0-F6B0-4023-85FB-44546B473E37Q24297234-46EDB816-18DC-4312-8A59-CDD4E1555C45Q24299360-8F8F263D-6151-45B1-8404-1093AA234D0CQ24301769-E2232B95-8BAD-442D-998B-E2459B3CD595Q24305141-9324C96D-68E8-4E76-A653-253F5B6E6951Q24318654-B084B168-D8C3-4575-868A-BD28B70A7CA3Q24337323-CA7C02AA-2EEA-4AED-BA84-7533ABC4E432Q24338881-536E60C7-A27B-498A-85A2-E4D508A450E0Q24647664-B86B093B-CC86-4536-8C4A-74DBC649D0A6Q24657532-5B65F3B4-E5F0-4C91-AD61-0B85BF5ED54EQ24658001-4E156E11-AE56-4E29-B466-E8520D3D45F7Q26777811-8F866591-DC95-4080-BAFA-A39A7AEBA9AAQ26779135-6B1FD7A3-5C2E-4B01-AFFE-DAC6E716956DQ26801131-C4CC7B6E-FAFE-45A1-867B-B20C21131BB3Q26825016-C930A831-02C2-44D2-8995-E763F2605266Q26991736-D7A4637D-B396-4CA6-BF81-7D4B053EDA1CQ27025174-5F951A97-D4C2-4CC0-BDE7-8AEE41FE5507Q27304385-9CF735C5-BE93-42B7-8175-0BA1A4FA5310Q27319063-8FC2DDFD-800C-4D0A-A765-452DB5B38785Q27334288-FDCE80AE-E944-422B-AB8D-3CE713E2EE5FQ27337616-8DB3D985-70F2-4DC0-BCC9-95E1B4D677AEQ27660495-4CD79ACA-6573-4FF9-89D0-5FD1DE78AF98Q27681896-2035D1F2-93BB-4D2C-95DB-8C7693785264Q27681935-0F3728EE-9E0C-49BB-AE06-1299870DDC0BQ27684872-D8018557-740A-4385-B16A-F610B362D8D9Q28078772-692B6353-8C1E-48DA-854A-54FD8AE5ED34Q28115589-B6789D2C-65C6-4429-9E6A-DB62F49F6345Q28235733-6E9D4CE6-7F92-4B81-840B-AAD145776458Q28472643-F06CDC4A-FCF9-48CB-84E3-4BA0D4FC3DC0Q28484219-C90CC94F-2067-4C7A-B4C7-DEE01759BFEBQ28488243-65D900C5-6814-4189-9B77-1608AB4475E6Q28539389-786B1E95-8CC8-4A44-A95A-386AFDE7E323Q28550236-55D29690-7FA7-41F7-B31E-3A69C24FD927Q28552326-1A8A47A0-42BD-4910-87FF-3D229A59F444Q28820936-65F091D0-BB55-4C9D-AF8F-9B28FB2C2FADQ30352390-E937110F-7FC6-4341-812A-2D46ED2FF51C
P2860
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@ast
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@en
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@nl
type
label
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@ast
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@en
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@nl
prefLabel
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@ast
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@en
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo.
@nl
P2093
P1433
P1476
BI 2536, a potent and selectiv ...... inhibits tumor growth in vivo
@en
P2093
Günther R Adolf
Jan-Michael Peters
Jens Quant
Martin Krssák
Martin Steegmaier
Matthias Grauert
Matthias Hoffmann
Norbert Kraut
Pilar Garin-Chesa
P304
P356
10.1016/J.CUB.2006.12.037
P407
P577
2007-02-08T00:00:00Z